Sign In
Buy ALT
$2.92
+0.0500 (+1.74%)
At Close: Jun 04, 2026
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
11:05am, Thursday, 21'st Aug 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options If you s
Contact The Gross Law Firm by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc.(ALT)
08:45am, Thursday, 21'st Aug 2025
NEW YORK , Aug. 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class per
ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc.
05:37pm, Wednesday, 20'th Aug 2025
SAN DIEGO , Aug. 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) secur
NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed ag
Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights – ALT
04:09pm, Tuesday, 19'th Aug 2025
NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
08:45am, Tuesday, 19'th Aug 2025
NEW YORK , Aug. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITIO
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
07:30am, Tuesday, 19'th Aug 2025
Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) --
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders to Contact the Firm for Information About Their Rights
06:44pm, Monday, 18'th Aug 2025
NEW YORK , Aug. 18, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities Altimmune, Inc. (NAS
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT
08:45am, Monday, 18'th Aug 2025
NEW YORK , Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class peri
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
12:37pm, Sunday, 17'th Aug 2025
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are adv
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
10:00am, Saturday, 16'th Aug 2025
NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised
NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June
Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)
12:06pm, Friday, 15'th Aug 2025
PHILADELPHIA , Aug. 15, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Compa
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquir
NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITIO
